Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Targeted Protein Degradation as a Therapeutic Strategy for the Treatment of Gastrointestinal Stromal Tumour (GIST) (Novel GIST Therapies)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-03-01
End date: 2027-02-28
Duration (months): 24.0
Total project cost (EUR): 165312.96
EU funding (EUR): 165312.96
Participants: 1
Project status: SIGNED

Gastrointestinal stromal tumour (GIST) is the most common subtype of sarcoma in humans and its initiation and progression is predominantly driven by constitutively activating mutations in the receptor tyrosine kinase (RTK) KIT. This dependency on KIT led to the approval of kinase inhibitors for the treatment of GIST. Inhibition of KIT activity is effective at treating GIST in the short-term however, the majority of patients eventually develop resistance. This resistance is predominantly due to the emergence of additional KIT mutations. Therefore, the development of alternative KIT targeting therapies, beyond the current state-of-the-art, is paramount for the effective treatment of GIST in the long-term. One such strategy is targeted protein degradation (TPD). TPD is based on drugs called “degraders” which are compounds that induce the proximity between a protein of interest (POI) and components of the cellular proteolytic machinery resulting in the destruction of the former. Degradation of KIT offers several benefits over inhibition, that may combat resistance in GIST. Firstly, small molecule inhibitors rely on a strong affinity for the POI to be effective whereas degraders can maintain activity when the affinity for the target is compromised by mutations. Secondly, inhibition of protein function is not a requirement for degrader activity and therefore additional ligandable sites on the POI. In this project, I will employ a multifaceted drug discovery approach with the overarching aim of designing, identifying, and optimising degraders of KIT and investigate their effectiveness in GIST models. In order to explore the full potential of TPD in the treatment of GIST, I will pursue two different modalities of degraders: (i) bivalent (Objective 1) and (ii) monovalent (Objective 2). With a clear clinical translational goal in mind, the optimised degraders will be evaluated in various preclinical models of GIST (cellular and organoid) (Objective 3).

Keywords: gastrointestinal,cancer,degraders,gist,organoids,receptor tyrosine kinase
III-Sb Quantum-Dot (QD) memory devices for applications in neuromorphic circuits (QDnEuroMemory)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-06-01
End date: 2025-05-31
Duration (months): 24.0
Total project cost (EUR): 211754.88
EU funding (EUR): 211754.88
Participants: 1
Project status: CLOSED

The current exponential growth of energy consumption by electronic devices is not sustainable in the long term and has detrimental effects on global climate change, it requires solutions to reduce energy waste. One novel approach is the Artificial Neural Network (ANN), which is more efficient in performing several tasks as learning, pattern recognition and vision than the usual electronics and sequential algorithms. However, ANN lacks specific hardware to reach its potential. Recently, a lot of effort has been done to find memory devices to implement truly efficient neuromorphic hardware. High endurance and retention time, and low write energy, low write time and voltage are required. This research program proposes to create these memory devices with III-Sb compound semiconductor nanostructures since they are expected to have all these properties. In addition, their optoelectronic properties will allow the manipulation of memory states using light, which will provide unrivaled functionalities to the ANN that use these novels III-Sb memories.

Keywords: molecular beam epitaxy,iii sb semiconductors,memory
Mobility for Urban Sustainability and the Environment CIVITAS 2030 Coordination and Support Action: Sustainable and Smart Mobility for All (CIVITAS MUSE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Cross-sectoral solutions for the climate transition
Action type: Coordination and support actions
Countries involved: Germany,Belgium,Italy,Portugal,Netherlands,Spain
Call: CIVITAS 2030 – Coordination and support for EU funded urban mobility innovation (HORIZON-CL5-2022-D2-01, 2022)
Start date: 2023-05-01
End date: 2027-04-30
Duration (months): 48.0
Total project cost (EUR): 4997957.5
EU funding (EUR): 4997957.5
Participants: 9
Project status: SIGNED

The CIVITAS Initiative will be led by a new CIVITAS MUSE Coordination and Support Action from 2023-2027, coordinated by ICLEI Europe and involving 8 expert partners in total. This project will deliver a wide range of services to the European Commission and its funded urban mobility-related projects, to enhance their results through further communication, capacity building and exploitation activities. These will involve and reach all parts of the urban mobility community, particularly CIVITAS project participants and EU cities. Further dissemination of the state of the art is made possible through CIVITAS MUSE by enhancing operational structures that involve wider community stakeholders such as the Secretariat, CIVINET regional and national networks, the Policy Advisory Committee, annual Conferences, a new Collective of European mobility networks, as well as improving collaboration groups between projects and their partners (and their related stakeholders and experts), at both a management and thematic/topic based level. The CIVITAS MUSE project helps to guarantee the replication of innovative solutions and results through a deployment planning cycle, working with cities through capacity building exchanges to promote solution-specific learning and broad skills development. Monitoring, extracting and communicating the most useful results and information from projects lies at the core of CIVITAS MUSE, with projects supported in employing up to date evaluation approaches. CIVITAS MUSE comes at a key time in the Smart and Climate Neutral Cities Mission and the achievement of multiple Destination goals including those under Cross-Sectoral Solutions for the Climate Transition.

Keywords: sustainable mobility,innovative measures,international cooperation
Targeted insula stimulations as treatment for autoimmune disorders (NEUROGUT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Israel
Call: ERC PROOF OF CONCEPT GRANTS2 (ERC-2022-POC2, 2022)
Start date: 2023-06-01
End date: 2024-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Inflammatory bowel diseases (IBD) are a group of chronic inflammatory conditions affecting the gastrointestinal (GI) tract, including Crohn’s and Ulcerative colitis. The prevalence of IBD has been increasing globally and almost doubled from 3.7 million in 1990 to 6.8 million in 2017, with the highest prevalence rates observed in Europe and North America (422 cases per 100,000 population). Patients with IBD suffer from chronic relapsing abdominal pain, urgency and incontinence, and depending on the severity of their presentation, are at risk of developing acute life-threatening complications (e.g., severe bleeding, fulminant colitis, perforation). Although these conditions primarily affect the GI tract, other organ systems, such as the eyes, skin, musculoskeletal system, and lungs, hepatobiliary and hematologic function might be affected as well. As of today, the etiology of the disease is largely unknown, and the current available treatments are limited in their efficiency and accompanied by significant side effects. These treatments largely target inflammatory mediators to suppress excess inflammation. These can include general immunosuppression such as high-dose corticosteroids, or more specific biological agents (e.g., anti-TNF). Patients with IBD are dependent on the lifelong administration of immunosuppressive drugs, exposing them to multiple adverse effects ranging from systemic infections to metabolic dysregulation and even cancer. Taken together, this is a systemic disease that affects many physiological systems and has a strong emotional component (). Yet, treatment with immune suppressive drugs can only alleviate some symptoms and cannot treat the source of the disease nor its broad systemic manifestations.
Latin American Chinese European Galaxy Formation Network (LACEGAL)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Staff Exchanges
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Spain,Germany,Netherlands,Chile,Mexico,China,United Kingdom,Italy,Argentina,Brazil
Call: MSCA Staff Exchanges 2021 (HORIZON-MSCA-2021-SE-01, 2021)
Start date: 2023-03-01
End date: 2027-02-28
Duration (months): 48.0
Total project cost (EUR): 1366200.0
EU funding (EUR): 1366200.0
Participants: 15
Project status: SIGNED

Spectacular breakthroughs in astronomy have been driven by a combination of observational advances and groundbreaking computer simulations. Simulations are now accepted as being essential for the interpretation and exploitation of astronomical data. Europe is a world leader in this area. Our aim is to build on a highly successful Horizon2020 RISE network to avoid fragmentation of expertise and concentration of supercomputer resources in a few groups. We will do this through international mobility between leading international centres in the subject. The LACEGAL objectives include addressing some of the biggest questions in science: • What is Dark Matter and how do its properties affect galaxies and galaxy clusters? • What is the Dark Energy behind the accelerating expansion of the Universe and how does it relate to the rest of physics? Is it a cosmological constant, a new form of mass-energy, or a low-energy deviation from Einstein's theory of gravity? • How did galaxies acquire their observed forms? What determines their characteristic properties? • How did our galaxy, the Milky Way, form and how can this be read from the "archeological" record preserved in its stellar populations? Our research program is ambitious and ground-breaking. It is only possible through the opportunity that the Staff Exchange provides to bring together world leaders in a wide range of areas to work on common problems. The exchange of researchers will provide the critical mass is necessary to deliver our program. LACEGAL will providing unique training opportunities and build lasting collaborations. LACEGAL will be key in allowing Europe to exploit its huge investment in observational facilities, such as the Euclid mission to probe the nature of dark energy, and to build European leadership in international projects, such as the Dark Energy Spectroscopic Instrument, Euclid, the Legacy Survey of Space and Time, and the Square Kilometre Array.
FLEXIBLE AMMONIA SYNTHESIS TECHNOLOGY FOR ENERGY STORAGE (FASTER-HOP ON)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Research and Innovation actions
Countries involved: Netherlands,Greece
Call: Hop-on facility (HORIZON-WIDERA-2025-03, 2025)
Duration (months): 36.0
Total project cost (EUR): 599375.0
EU funding (EUR): 599375.0
Participants: 2
Project status: CLOSED

The overall goal of the FASTER project is to develop and validate a flexible, mild-temperature NH₃ synthesis system, especially suited for small- to medium-scale applications, boosting decentralized production of green NH₃ as an energy and H2 vector. Building upon this, the Hop-on project aspires to complement the ambitious FASTER initiative by addressing the equally critical and challenging step of NH₃ cracking to H2. This process is central to the “NH₃ as H2 carrier” concept, which requires that NH₃ be seamlessly decomposed into N2 and H2, followed by efficient separation to deliver high-purity H2 to end-users. To achieve this, CERTH will adopt the approach being developed in FASTER for NH₃ synthesis in order create an NH₃ decomposition catalytic material. The catalyst will be incorporated with membrane separation technologies based on metal and inorganic membranes for in-situ and ex-situ separation of hydrogen, ensuring methodological consistency with the FASTER project. This strategy allows tailored optimization of catalytic materials, reactor design, and process conditions specifically suited to the requirements of NH₃ cracking. The widespread implementation of “NH₃ as H2 carrier” will therefore depend critically on the ability to perform efficient, scalable, and flexible NH₃ cracking. This challenge is further intensified by the need to accommodate decentralized, small- to medium-scale applications. By directly addressing these knowledge gaps and technological barriers, the Hop-on project not only enhances the scope of FASTER but also aligns strongly with the WIDERA objectives of expanding ongoing research programs, strengthening European research capacity, and enabling energy transition.

Keywords: ammonia cracking,membrane reactors,joule heated reactors
Decoding Death and Dying in people with Dementia by Digital thanotyping (5-D)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Norway
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

How can we recognize that a person with dementia is at the end of life? When we are dying, our physical, mental, and social abilities are gradually declining. No reliable method of predicting perceived dying currently exists although the technology is available (sensors, algorithms). The aim of Decoding Death and Dying in Dementia by Digital thanotyping (5-D) is to provide methods and tools to diagnose and describe dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now, focusing on the case of dying people with dementia as one of the most vulnerable and difficult to study groups. 5-D combines clinical assessment tools with wearable sensing technology to monitor a) pain and distressing symptoms, b) behavioral and psychological symptoms in dementia (BPSD), c) oral changes, and to decode “the point of no return” as the beginning of perceived dying. To obtain this outcome in nursing home patients with dementia, I will test the main hypothesis: from monitoring the evolution of thanotype components over time and their interdependencies, the prediction of the “point of no return” is possible. The objectives of 5-D are: O1. Collect data using sensors and validated assessment scales. O2. Develop estimation methods for BPSD from sensor measurements. O3. Develop digital tools to capture the expression of pain. O4. Determine the relationship between breathing and oral symptoms. O5. Develop models for symptom interdependencies at the end of life and the “point of no return”. O6. Perform human-in-the-loop validation of developed tools, models, and algorithms. The ground-breaking interdisciplinary novelty of 5-D endeavors to enhance our understanding of end-of-life underlying pain and symptoms in people with dementia. Advancing our theoretical knowledge to uncover how, when, and why perceived dying can be identified opens the doors for transferable research across several scientific fields.

Keywords: wearable devices,pain and distressing symptoms at the end of life,systems modeling,human in the loop validation
Light-reconfigurable substrate for cell cultures (L-Cell)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Finland
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-08-01
End date: 2024-01-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

L-Cell is a method for robust, reconfigurable control of surface topography, based on creating reversible light-induced surface structures onto azobenzene-containing bilayers. These light-reconfigurable substrates allow free-form topographical patterns to be created and subsequently erased over many cycles on a biocompatible cell culture substrate, even when the cells are already growing on the substrate. L-Cell aims at mimicking more closely the dynamic conditions in human body, which regulate many physiological and pathological processes, such as tissue morphogenesis, healing, and tumour growth. Our non-invasive solution is important for definition of chrono-programmes e.g. cell differentiation, stem cell phenotype harvesting, tissue regeneration and triggering cell directional migration. The bilayer structure allows for easy chemical modification of the surface, ensuring biocompatibility and further functionalization, and fully supporting existing protein deposition techniques. L-Cell reconfigurable light-responsive petri dishes can be used as drop-in solution, enabling new, unique biological investigations on cell dynamics to be conducted. Besides, the growing need to reduce animal testing in drug screening, toxicology, and research has increased the demand for innovative cell culture solutions that recapitulate the complexity of cell dynamics in a controllable, cost-effective way, without sacrificing their clinical relevance. For all these reasons, L-Cell offers new opportunities as an innovative tool for a wealth of potential targets.
Future storage systems for the energy transition: Polymer-based redox-flow batteries (FutureBAT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure -properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 2499355.0
EU funding (EUR): 2499355.0
Participants: 1
Project status: SIGNED

The efficient storage of electric energy represents a major challenge for a successful energy transition, enabling the utilization of fluctuating renewable resources also as base load. Redox-flow-batteries (RFBs) are the only type of battery where intrinsically power and capacity can be varied independently from each other, making this type of battery perfectly suited for scalable stationary applications. RFBs based on aqueous electrolytes with organic / polymer active materials have the potential to be suitable alternatives for commercial metal-based RFBs, with low CO2 footprint perfectly fitting to the goals of the EU Green Deal. In particular, polymer-based RFB systems enable the use of cost-efficient dialysis membranes together with pH neutral table salt solutions as electrolytes. Nevertheless, systems still reveal restrictions in terms of capacity, lifetime and temperature-stability. FutureBAT targets a breakthrough in the development of novel organic active materials for RFBs, by combining the search for new active entities with the improvement of current polymeric materials on the molecular level, by this providing new functions / properties. The key question will be how far polymeric electrolytes can be tuned by adjusting the molecular structure. Advanced polymer structures (incl. (hyper-) branched structures) and colloidal systems (with varied morphologies) as well as novel hybrid organic systems will provide access to hitherto unknown properties, e.g., new photo-rechargeable RFBs or RFBs having all charged species within one single tank. Furthermore, new sensor systems (SOC and SOH) will be applied, which also will form the basis for novel 3D-printed lab cells for (high-throughput) screening. As the outcome, pioneering breakthroughs in the field of polymer-based RFBs will be enabled, surely targeting high risk / high gain step-changing research but built up on the know-how of one of the leading international research teams in this rather new field.

Keywords: redox flow batteries,redox active polymers,energy storage